George Rehm is a founding partner of aeris CAPITAL AG. He joined aeris in 2004 and has over thirty years of experience as a lawyer and executive in international licensing, technology transfer and investment and privatization transactions in the US, Europe and Asia. He has held board or observer positions in numerous transformational healthcare companies, including Crescendo Biosciences, Adamas Pharmaceuticals, Ion Torrent, Inc. Currently, from a base in Northern California, he serves as a director of GenomeDx Inc., PFS Genetics, Butterfly Networks, LAM Therapeutics Inc., Solstice Biosciences and Jiff Inc. Prior to joining aeris, Mr. Rehm worked as legal counsel for numerous international technology transfer transactions and served as chief European consultant to Bristol-Myers Squibb on an oncology care project, which involved delivery of services through ambulatory clinics throughout the EU, after establishing law offices in the former Eastern Germany, the Czech Republic and Russia on behalf of US and German law firms. He received his BSFS from Georgetown University, and a JD from UC Law San Francisco in parallel to graduate studies in City Planning at the College of Environmental Design, UC Berkeley and served as graduate assistant at the Earl Warren Legal Institute, UC Berkeley, Boalt Hall. Mr. Rehm has written and lectured frequently in Germany and the US on international trade, investment, technology transfer, health care, and venture capital and is fluent in both German and English.